Paul Jackson

Title: Paul Jackson: Innovator in Central Nervous System Regeneration

Introduction

Paul Jackson is a notable inventor based in Brookline, MA (US). He has made significant contributions to the field of neuroscience, particularly in the area of central nervous system regeneration. His work focuses on the molecular factors that promote nerve cell regeneration, which has important implications for treating spinal cord injuries and other nervous tissue damage.

Latest Patents

Paul Jackson holds a patent for "Trophic factors for central nervous system regeneration." This patent describes the development of cell culture conditions that maintain retinal nerve cells in well-defined, serum-free environments. The research characterizes molecular factors that stimulate axonal regeneration from these neurons. Notably, the glial sheath cells surrounding the optic nerve axons release two key molecules that trigger and sustain nerve regeneration. The first molecule, known as axogenesis factor 1 (AF-1), is a low molecular weight polypeptide approximately 1000 daltons in size. The second molecule, referred to as AF-2, is a larger protein with a size of around 12,000 daltons. Studies indicate that these factors play a crucial role in central nervous system regeneration, making them valuable for therapeutic applications.

Career Highlights

Paul Jackson is affiliated with the Children's Medical Center Corporation, where he continues to advance research in the field of neuroscience. His innovative work has garnered attention and respect within the scientific community, contributing to a better understanding of nerve regeneration mechanisms.

Collaborations

Some of his notable coworkers include Larry I Benowitz and Carleen Ann Irwin. Their collaborative efforts have furthered research in the area of central nervous system regeneration.

Conclusion

Paul Jackson's contributions to the field of neuroscience, particularly through his patent on trophic factors for central nervous system regeneration, highlight his role as an innovator. His work has the potential to significantly impact the treatment of spinal cord injuries and other nervous tissue damage.